Jazz Pharmaceuticals Engages Investors with Key Updates on Zanidatamab in January 2026

Jazz Pharmaceuticals Sets Stage for Major Investor Engagements in January 2026

Jazz Pharmaceuticals plc, a leader in innovative therapies for serious diseases, announces its participation in two pivotal investor events scheduled for January 2026. Central to these events is the anticipated review of results from the Phase 3 zanidatamab HERIZON-GEA-01 trial. Set for January 9, 2026, at 6:30 a.m. PT / 3:30 p.m. GMT, the investor webcast will feature insights from senior management and Dr. Geoffrey Ku of Memorial Sloan Kettering Cancer Center. This presentation follows an oral presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, where the trial results are expected to showcase the efficacy and potential of zanidatamab in treating specific cancer types.

The significance of the HERIZON-GEA-01 trial lies in its potential to enhance Jazz Pharmaceuticals’ already robust oncology portfolio, which is a key focus area for the company. By participating in these high-profile events, Jazz aims to communicate its strategic direction and advancements in cancer treatment, thereby reinforcing its commitment to improving patient outcomes. The webcast will be accessible via the Investors section of the company’s website, allowing stakeholders to engage with the latest findings and developments directly from the source. Furthermore, replays will be available for 30 days, ensuring that the information reaches a broader audience.

In addition to the webcast, Jazz Pharmaceuticals will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. CEO Renee Gala will provide a comprehensive overview of the company’s strategy and business updates during her presentation at 11:15 a.m. PST / 7:15 p.m. GMT. This engagement is crucial for articulating Jazz's vision and growth trajectory, particularly as it continues to expand its portfolio in oncology and neuroscience. The combination of these events underscores Jazz Pharmaceuticals' proactive approach in keeping investors and stakeholders informed about its innovative developments and strategic initiatives.

In summary, Jazz Pharmaceuticals is poised to leverage these significant investor events to underscore its commitment to research and innovation in oncology. By sharing insights from pivotal clinical trials and showcasing its strategic direction, the company aims to strengthen investor relations and highlight its role as a leader in providing life-changing therapies for patients. With a diverse portfolio and a focus on serious diseases, Jazz continues to position itself as a key player in the pharmaceutical industry. More information is available on their website, www.jazzpharmaceuticals.com.